VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with T2DM and CAS as defined below       │ Patients with T2DM and CAS as defined below        │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical definitions                              │ Clinical definitions                               │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CAD:Presence of any one of the following: Angina  │ CAD:Presence of any one of the following: Angina   │     100 │
│ plus positive exercise tolerance test, enzyme     │ plus positive exercise tolerance test, enzyme      │         │
│ and/or Q wave positive myocardial infarction,     │ and/or Q wave positive myocardial infarction,      │         │
│ angiographic evidence ( \>50% stenosis of one     │ angiographic evidence ( >50% stenosis of one       │         │
│ vessel), percutaneous or surgical coronary        │ vessel), percutaneous or surgical coronary         │         │
│ revascularisation                                 │ revascularisation                                  │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Aged between 18 and 75                            │ Aged between 18 and 75                             │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Provided written consent for participation in the │ Provided written consent for participation in the  │     100 │
│ trial prior to any study-specific procedures or   │ trial prior to any study-specific procedures or    │         │
│ requirements                                      │ requirements                                       │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication to Clopidogrel                   │ Contraindication to Clopidogrel                    │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Smoking (current smokers and patients who quit    │ Smoking (current smokers and patients who quit     │     100 │
│ smoking less than six months)                     │ smoking less than six months)                      │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Malignancy(diagnosed or under investigation)      │ Malignancy(diagnosed or under investigation)       │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Haematological disorders (Anaemia, malignancy,    │ Haematological disorders (Anaemia, malignancy,     │     100 │
│ bleeding disorders)                               │ bleeding disorders)                                │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of child-bearing potential                  │ Women of child-bearing potential                   │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of corticosteroids/other antithrombotic       │ Use of corticosteroids/other antithrombotic        │     100 │
│ agents(warfarin)                                  │ agents(warfarin)                                   │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic liver disease (Cirrhosis, malignancy and  │ Chronic liver disease (Cirrhosis, malignancy and   │     100 │
│ patients with more than twice the upper limit of  │ patients with more than twice the upper limit of   │         │
│ liver function tests)                             │ liver function tests)                              │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unable to consent                                 │ Unable to consent                                  │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of other investigational study drugs within 1 │ Use of other investigational study drugs within 1  │     100 │
│ year prior to study entry                         │ year prior to study entry                          │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous participation in this study              │ Previous participation in this study               │     100 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ T2DM: Diagnosed according to the WHO criteria     │ T2DM: Diagnosed according to the WHO criteria [53] │      98 │
│ \[53\]                                            │                                                    │         │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 75 Years │ T2DM: Diagnosed according to the WHO criteria [53] │      34 │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Malignancy(diagnosed or under investigation)       │      36 │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 92.66666666666667
OverAll Ratio: 94.83333333333334
